VitaDAO is a community owned collective funding early stage longevity research,governed by $VITA-holders 🧬
Ethereum
- Tweets 8,571
- Following 5,810
- Followers 44,301
- Likes 12,396
Pinned Tweet
Welcoming Michael Torres, Ph.D. (@Mykalt45) as a Core Advisor to VitaDAO.
From lab bench → clinic → a ~$300M Eli Lilly acquisition (CrossBridge Bio). Co-founder of ReCode. The scientist behind VitaRNA.
Now helping build our crypto Ă— biotech playbook. đź’›
vitadao.com/blog/michael-tor…
9
11
68
8,989
Rubedo is taking RLS-1496 into androgenetic alopecia.
First GPX4 modulator clinical study in hair loss. Starts Oct 2026. Data H1 2027.
Ex vivo elongation vs vehicle; highest dose trended above finasteride.
A project backed by the VitaDAO community. 👉 businesswire.com/news/home/2…
6
1
23
2,129
Could protecting the blood–brain barrier help tackle Alzheimer’s?
A new study links fibronectin buildup to APOE4-related barrier damage. Reducing it restored barrier function in experimental models.
Whether that protects memory remains untested.
nature.com/articles/s43587-0…
1
1
13
1,487
.@TimDraper , in Cryptonite:
“Decentralize the funding. Decentralize the data. Decentralize the right to be wrong in public.”
Science works best when it stays provisional
- open to challenge, not locked as doctrine.
Early longevity biology needs that same room:
- competing hypotheses, public misses, and capital that does not wait for a decades-long lifespan proof.
cryptoniteventures.substack.…
2
3
20
1,713
VitaDAO đź’› retweeted
Semaglutide extended lifespan in aged female mice — Feng, Barthez et al., Danica Chen lab, in Nature today.
3 months of GLP-1R agonism at 20 months old improved function, dialed down hallmarks of aging, hit conserved nutrient-sensing pathways. Head-to-head vs calorie restriction: CR-mimetic on most axes, better than CR on exploratory drive, spatial memory, glucose control.
We argued in Nature Health earlier this year that GLP-1 agonists deserve rigorous longevity testing. This is exactly that test.
doi.org/10.1038/s41586-026-1…
#longevity #aging #GLP1
11
25
63
3,152
Cerrato et al. in Nature Aging: a consensus roadmap toward precision senescence medicine.
It comes out of the SENESCENCE2030 meeting in Coimbra.
The next step is the unglamorous one: biomarkers and trial designs that can actually test a senolytic.
🧬 nature.com/articles/s43587-0…
Online now! Cerrato et al propose a consensus roadmap towards precision senescence medicine, emerging from the SENESCENCE2030 meeting in Coimbra, Portugal earlier this year @marc_dema nature.com/articles/s43587-0…
1
7
1,809
Agreed the endpoints have to be things people can feel.
RAPA-EX-01, co-funded by VitaDAO, tested rapamycin plus exercise in adults 65-85 with a 30-second chair stand as the primary endpoint. It missed, and the result is public.
Functional readouts, either way they land.
longevity biotech has a problem
we argue about semantics, call each other deathists, complain that nobody funds us and nobody cares
all while a weight loss tx class (w/ anti-aging signal) outsells every drug class ever
so mby let’s start making more drugs people actually want – ones that make them stronger, smarter, sexier – and simultaneously affect their aging trajectory?
consumer biotech might fix most of what's broken in the field
full thesis below
2
1
7
1,672
First human dosed with ER-100.
First time in-vivo partial epigenetic reprogramming designed to reverse cellular aging has been tested in a patient. Phase 1, open-angle glaucoma and NAION.
No efficacy readout here. First dose only.
August newsletter clinical highlight.
👉 vitadao.com/blog/vitadao-lon…
The VitaDAO August Longevity Newsletter is live.
This month:
- Artan Bio closed a $1M seed to advance ARTAN-102, a suppressor tRNA for CGA→TGA nonsense mutations. Still preclinical
- Gero added $17M, taking equity to $34M
- Rubedo RLS-1496: 46% vs 11% AK lesion-count drop at 4 weeks vs the untreated arm (first 18 of 24, open-label)
- A White House report notes DAOs are beginning to fund scientific research without traditional institutional gatekeepers
👉 Read here: vitadao.com/blog/vitadao-lon…
3
17
2,921
VitaDAO đź’› retweeted
We're live.
Brad Stanfield on the VitaDAO co-funded rapamycin & exercise results, then Tim Peterson on VitaLabs Synthetic Lethality.
nitter.net/i/broadcasts/1DxleVMEz…
3
4
19
2,215
We're live.
Brad Stanfield on the VitaDAO co-funded rapamycin & exercise results, then Tim Peterson on VitaLabs Synthetic Lethality.
Q&A after
VitaDAO Community Call: Rapamycin & Exercise — Results with Dr Brad Stanfield nitter.net/i/broadcasts/1DxleVMEz…
1
3
13
1,888
VitaDAO Community Call: Rapamycin & Exercise — Results with Dr Brad Stanfield nitter.net/i/broadcasts/1DxleVMEz…
2
10
2,588
VitaDAO đź’› retweeted
VitaDAO Community Call tomorrow: Tue 25 Aug · 19:00 CEST / 10:00 PDT.
@BradStanfieldMD presents results from the VitaDAO co-funded rapamycin & exercise study.
Dr Tim Peterson follows with an update on VitaLabs Synthetic Lethality: synergistic drug combinations for multiplicative longevity effects.
Q&A after.
👉 luma.com/236izd9j/
1
6
25
2,539
The VitaDAO August Longevity Newsletter is live.
This month:
- Artan Bio closed a $1M seed to advance ARTAN-102, a suppressor tRNA for CGA→TGA nonsense mutations. Still preclinical
- Gero added $17M, taking equity to $34M
- Rubedo RLS-1496: 46% vs 11% AK lesion-count drop at 4 weeks vs the untreated arm (first 18 of 24, open-label)
- A White House report notes DAOs are beginning to fund scientific research without traditional institutional gatekeepers
👉 Read here: vitadao.com/blog/vitadao-lon…
3
11
24
15,792
Remedium Bio, backed by the VitaDAO community, turns fat cells at the injection site into a long-term, dose-adjustable protein factory (Prometheus).
Planned $10M Series A initial close. Lifespan Vision led; Eli Lilly and HKX Capital in.
Still preclinical.
prnewswire.com/news-releases…
1
2
8
14,673
VitaDAO đź’› retweeted
Connecting the dots back to @artan_bio. Our drugs have the ability to suppress these other somatic mutations involved in aging. A real chance to move the needle of lifespan and healthspan! Grateful to the DeSci/crypto space for supporting this idea with ethereum:0x7b66e84be78772a3afaf5ba8c1993a1b5d05f9c2.
TP53 alterations remain a powerful risk signal in newly diagnosed DLBCL. Daniel Landsburg of @Penn reviewed functional status, VAF and genomic context—and why TP53-mutant disease warrants better targeted strategies. #DAVAHeme
6
18
3,174
VitaDAO đź’› retweeted
Thanks @Ben_M_McLeod for giving me space! Great setup you guys have! Excited to continue building especially in the DeSci space. Crypto ($vitarna) + biotech is real and spectacular! @vitadao @vitarnabio @artan_bio @Bodeeeman @aschwartzphd
Michael Torres sold his company for $300 million to Eli Lilly.
This is the timeline of how he got there.
What is he up to next?
Among other things, a longevity gene therapy that uses some fascinating tRNA biology (blockchain is involved).
Many thanks to @Mykalt45 for your time!
1
9
19
3,642
VitaDAO đź’› retweeted
Excited to share one of the amazing companies I’m working on!
Join here tomorrow!
piped.video/watch?v=epGxlQsg…
@artan_bio @vitarnabio @Molecule_sci @BioProtocol @vitadao @Bodeeeman @aschwartzphd
1
5
25
1,642
